Developer of exosomes to deliver safe, highly targeted medicines. The company has developed REVEAL, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas. The company was founded in 2016 and headquartered in San Francisco, United States. It has raised $44.1M in series a funding, with backing from Samsung Securities, 8VC, Viking Global Investors, Illumina, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Clinical Genomics, Life Sciences - Drug Delivery space. The company's offerings encompass Drug Delivery - Extracellular Vesicles Based - Exosome Based, Genomics - Applied Genomics - Clinical Genomics - Therapeutics.
← All startups
Mantra Bio
Series ADeveloper of exosomes to deliver safe, highly targeted medicines. The company has developed REVEAL, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas. The company was founded in 2016 and headquartered in San Francisco, United States. It has raised $44.1M in series a funding, with backing from Samsung…
About
Business model
Drug Delivery > Extracellular Vesicles Based > Exosome Based,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Samsung Securities8VCViking Global InvestorsIlluminaBoxGroupAllen & CompanySpringboard Enterprises
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.